בליאומיצין PFI

Kraj: Izrael

Język: hebrajski

Źródło: Ministry of Health

Składnik aktywny:

BLEOMYCIN SULFATE

Dostępny od:

MEGAPHARM LTD

Kod ATC:

L01DC01

Forma farmaceutyczna:

אבקה להכנת תמיסה לזריקה

Skład:

BLEOMYCIN SULFATE 15000 IU/VIAL

Droga podania:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Typ recepty:

מרשם נדרש

Wyprodukowano przez:

BAXTER ONCOLOGY GmbH, GERMANY

Grupa terapeutyczna:

BLEOMYCIN

Dziedzina terapeutyczna:

BLEOMYCIN

Wskazania:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Data autoryzacji:

2020-09-30